1. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 2006; 351:192–197. PMID:
17055458.
Article
2. Paffhausen T, Schwab M, Westermann F. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett. 2007; 250:17–24. PMID:
17141950.
Article
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353:172–187. PMID:
16014887.
Article
4. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002; 20:325–334. PMID:
11773186.
Article
5. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, et al. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer. 2003; 106:147–152. PMID:
12800187.
6. Meyer N, Kim SS, Penn LZ. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 2006; 16:275–287. PMID:
16945552.
Article
7. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983; 305:245–248. PMID:
6888561.
Article
8. Schwab M. MYCN in neuronal tumours. Cancer Lett. 2004; 204:179–187. PMID:
15013217.
Article
9. Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets. 2005; 5:273–283. PMID:
15975048.
Article
10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295:139–145. PMID:
10991971.
11. Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984; 44:5444–5449. PMID:
6488196.